News | November 30, 2022
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics
The committee unanimously decided to confer the Lifetime Achievement Award to Kiran Mazumdar-Shaw for her monumental contributions as a global leader in biotechnology innovation and entrepreneurship
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
The company is eligible for 12 months exclusivity from launch
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Subscribe To Our Newsletter & Stay Updated
